Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. CT ORDER Other Confidential Order
  2. 4 Open-market sale President and CEO sold 18,334 shares at an average $18.09 ($331,664)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 10-Q Report Quarterly Report
  6. 8-K Event Results of operations · Executive or director change
  7. 8-K Event Material agreement · Regulation FD disclosure
  8. 4 Open-market sale President and CEO sold 18,333 shares at $21.72 ($398,193)
  9. 4 Open-market sale Chief Medical Officer sold 17,500 shares at $21.72 ($380,100)
  10. 4 Option exercise COO and Secretary acquired 7,043 shares (option exercise)
  11. 4 Open-market sale Chief Medical Officer sold 17,500 shares at $19.05 ($333,375)
  12. 4 Open-market sale President and CEO sold 18,333 shares at $19.06 ($349,427)
  13. 4 Open-market sale Chief Medical Officer sold 17,500 shares at $18.04 ($315,700)
  14. 4 Open-market sale President and CEO sold 18,334 shares at $18.05 ($330,929)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 10-Q Report Quarterly Report
  19. 8-K Event Results of operations
  20. 8-K Event Other events

Page 35 of 40 · 789 filings